Clinical Trial Update: Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

View source ↗

Summary

A terminated clinical trial investigating predictors of disease progression in atypical hemolytic uremic syndrome, including genetics and biomarkers, with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome | Status: TERMINATED | Results posted: 2020-01-02